Rigrodsky & Long, P.A. Announces Investigation Of MAP Pharmaceuticals, Inc. Buyout

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of MAP Pharmaceuticals, Inc. (“MAP” or the “Company”) (NASDAQ GS: MAPP) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Allergan, Inc. (“Allergan”) (NYSE: AGN) in a transaction valued at approximately $958 million, on a fully-diluted basis.

Click here to learn more: http://www.rigrodskylong.com/investigations/map-pharmaceuticals-inc-mapp.

Under the terms of the proposal, public shareholders of MAP will receive $25.00 per share in cash for each share of MAP they own.

The investigation concerns whether MAP’s board of directors failed to adequately shop the Company and obtain the best possible value for MAP’s shareholders before entering into an agreement with Allergan.

If you own the common stock of MAP and purchased your shares before January 22, 2013, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Peter Allocco at Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, New York 11530 toll free at (888) 969-4242, by e-mail to info@rigrodskylong.com, or at: http://www.rigrodskylong.com/investigations/map-pharmaceuticals-inc-mapp.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

Copyright Business Wire 2010

If you liked this article you might like

Allergan's Healthy Prospects

Cramer's 6 Stocks in 60 Seconds: SNV TXN UL CREE MAPP KBH (Update 1)

2013 FDA Drug Approval Decision Calendar

Biotech Stock Mailbag: Aveo, Anthera, Amarin, MAP Pharma

MAP Pharma's Awkward FDA Silence